Login
Canopy Growth NYSE: CGC
From product and process innovation to market execution and everything in between, we are driven by a passion for …. providing medical and recreational cannabis consumers the best possible experience
| Name | Canopy Growth |
| Ticker | CGC |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Cannabis Specialties |
| Price | 35.31 |
| 52W Low/High | 9.73 / 52.17 |
| Market cap | 13 B |
| 1Y Total Return |
73.94%
Strong |
| 1Y Volatility |
83.90%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
From product and process innovation to market execution and everything in between, we are driven by a passion for …. providing medical and recreational cannabis consumers the best possible experience
Details
| Ticker | CGC |
| Name | Canopy Growth |
| ISIN | CA1380351009 |
| CUSIP | |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Cannabis Specialties |
| Country | Canada |
| Currency | U.S. Dollar |
Share as of 2/23/21
| Close Price | 35.31 |
| 52W Low/High | 9.73 / 52.17 |
| Market cap | 13 B |
| 1Y Total Return |
73.94%
Strong |
| 1Y Volatility |
83.90%
High Risk |
| Beta | 3.06 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -116.2% |
| Cash from Op. / Cur. Liabilities | -1.70 |
| Diluted Earnings / Share | -1.17 |
| ROE | - |
| ROIC | -8.9% |
| Price / Revenue | 33.2 |
| Price / Book | 4.2 |
| Price / CF | -28.3 |
| Current Ratio | 6.2 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.16 |
| in Mils USD |
rolling-year up to December
|
|||||
|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
397
|
294
|
115
|
55
|
-
|
|
| Gross Profit |
-
|
47
|
-
|
50
|
-
|
|
| R&D |
-32
|
-6
|
5
|
0
|
-
|
|
| EBITDA |
-455
|
-246
|
-290
|
3
|
-
|
|
| Operating Income |
-1,662
|
-697
|
-364
|
-41
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
| per Share | ||||||
| Diluted avg Shares |
373
|
349
|
316
|
-
|
-
|
|
| EPS exc. Extra |
-1.17
|
-1.42
|
-1.95
|
-
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
4,948
|
6,142
|
6,400
|
860
|
-
|
|
| Cash, Eq & Invt ShortTerm |
1,259
|
1,731
|
3,641
|
187
|
-
|
|
| Total Current Assets |
1,703
|
2,422
|
3,909
|
294
|
-
|
|
| Total Non-Current Assets |
3,245
|
3,720
|
2,491
|
566
|
-
|
|
| Intangibles |
1,792
|
2,012
|
1,470
|
314
|
-
|
|
| Total Liabilities |
1,579
|
1,921
|
901
|
59
|
-
|
|
| Total Current Liabilities |
273
|
319
|
219
|
23
|
-
|
|
| Long Term Debt |
1,306
|
1,601
|
682
|
36
|
-
|
|
| Shareholder equity |
3,103
|
4,012
|
5,354
|
763
|
-
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-465
|
-612
|
-246
|
-47
|
-
|
|
| Depreciation |
109
|
76
|
21
|
15
|
-
|
|
| Cash from Investing |
-310
|
-1,316
|
-1,392
|
-103
|
-
|
|
| Capex |
499
|
882
|
433
|
78
|
-
|
|
| Cash from Financing |
233
|
8
|
4,433
|
265
|
-
|
|
| Stock Issued |
224
|
95
|
4,026
|
268
|
-
|
|
| Debt (LT) Issued |
9
|
-97
|
440
|
-1
|
-
|
|
| Free Cash Flow |
-665
|
-1,347
|
-1,030
|
-
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.2
|
7.6
|
17.8
|
12.8
|
-
|
|
| Financial Leverage D/E |
0.16
|
0.11
|
0.11
|
0.01
|
-
|
|
| Return on Capital Avg |
-8.9%
|
-7.9%
|
-4.4%
|
-5.0%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available